@article{JTD24127,
author = {Katsuhiro Okuda and Hiroshi Haneda and Keisuke Yokota and Tsutomu Tatematsu and Ryoichi Nakanishi},
title = {The effect of smoking and TP53 mutations on molecular-targeted therapy in lung adenocarcinoma patients},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 33},
year = {2018},
keywords = {},
abstract = {The treatment of non-small cell lung cancer (NSCLC) reached a major turning point with the discovery of gefitinib as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and the identification of EGFR mutations in 2004 (1).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/24127}
}